Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 3, 2006

Diagnocure Gains Rights to New Prostate Cancer Genes

  • DiagnoCure acquired specific rights and commissioned further research on new genes that show promise as prostate cancer markers. The agreement, signed with Radboud University Medical Center, Nijmegen, the Netherlands, covers technology rights related to Dr. Jack Schalken’s discoveries of the role of FOX gene expression in prostate cancer and commissions further research into the diagnostic, prognostic, and therapeutic potential of those genes.

    “We have sufficient evidence to indicate that specific FOX genes may further enhance the diagnostic efficacy of the PCA3 gene, which in itself reflects a dramatic improvement over PSA testing,” asserts Dr. Schalken.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »